

West London Mental Health NHS Trust Performance in Initiating Q4 15/16

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Comments	Reasons for delay correspond to:
161812/LNW	A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)	06/07/2015	07/07/2015	No		1			No	Many of the patients seen gave consent to participate in the trial but screen failed on inclusion/exclusion criteria. We are also still awaiting an SSA exemption for using the contracted PET imaging centre which has thus delayed the screening procedures and further delaying the speed at which patients will be recruited into the study.	Neither

West London Mental Health NHS Trust Performance in Delivery Q4 15/16

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Comments
150835/LNW	DEME 3598 - STARBRIGHT Randomised, double blind, parallel- group, placebo-controlled study of Lu AE58054 in patients with mild moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor; study 3	Number Agreed	8	8	Date Agreed	17/03/2016	3	17/03/2016	1st patient was recruited on the 28/08/15